PMID-33196464 – Kisspeptin Receptor Agonist for Female Reproductive Disorders
Abbara A, Phylactou M, Clarke SA, Eng PC, Sheridan R, Mills EG, Sheridan B, Dhillo WS. "Kisspeptin receptor agonist for IVF timing and reproductive disorders," J Clin Invest, 2020;130(12):6739-6753.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33196464 |
| DOI | 10.1172/JCI139681 |
| Year | 2020 |
| Journal | The Journal of Clinical Investigation |
| Study Type | Human Clinical (Comparative) |
| Evidence Level | II |
| Sample | Healthy women, women with PCOS, and women with hypothalamic amenorrhea |
| Peptide(s) Studied | Kisspeptin-10 |
Key Findings
- Compared MVT-602 (long-acting kisspeptin agonist) with native kisspeptin-54 (KP-54) across three female populations
- In healthy women: both MVT-602 and KP-54 stimulated LH release, with MVT-602 showing a more sustained response
- In PCOS patients: kisspeptin agonism effectively triggered LH surges suitable for oocyte maturation
- In hypothalamic amenorrhea: kisspeptin restored pulsatile GnRH/LH secretion
- Kisspeptin-based IVF triggering may reduce the risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG
- Demonstrates therapeutic potential across multiple reproductive disorder phenotypes
- Supports kisspeptin as a physiological regulator that can be harnessed for more natural HPG axis activation
Study Design
Multi-cohort clinical study comparing subcutaneous MVT-602 (kisspeptin receptor agonist) with native kisspeptin-54 in three groups: healthy women, women with PCOS, and women with hypothalamic amenorrhea. Assessed LH, FSH, estradiol responses, and LH pulsatility. Multiple dosing regimens evaluated.
Limitations
- Not a single randomized controlled trial; multiple small cohorts with different endpoints
- MVT-602 is a proprietary kisspeptin agonist, not identical to commercially available kisspeptin-10
- Long-term reproductive outcomes (pregnancy rates) not assessed in this study
- Translational gap between kisspeptin-54/MVT-602 and shorter kisspeptin-10 peptide products
Clinical Relevance
This JCI publication is significant because it demonstrates kisspeptin's therapeutic versatility across the spectrum of female reproductive disorders. For IVF clinics, kisspeptin-based triggering could reduce OHSS risk — a major clinical concern. For practitioners using kisspeptin-10, this study supports the peptide's role in HPG axis modulation for fertility, PCOS management, and functional hypothalamic amenorrhea. The data positions kisspeptin as a more physiological alternative to exogenous gonadotropins and GnRH agonists.
Related
#research #observational #evidence-level-II